Literature DB >> 27272727

Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.

Nicola Squillace1, Patrizia Lorenzini2, Giuseppe Lapadula3, Alessandra Bandera3, Alessandro Cozzi-Lepri4, Stefano Rusconi5, Massimo Puoti6, Antonella Castagna7, Andrea Antinori2, Andrea Gori3, Antonella d'Arminio Monforte8.   

Abstract

OBJECTIVES: Our primary aim was to study diabetes mellitus (DM) arising during combination ART (cART) and to attempt to identify associations between these cases and triglycerides (TRG) and the TRG to HDL-cholesterol (TRG/HDL) ratio. Our secondary aim was to analyse the association between DM development and hepatic fibrosis.
METHODS: This was a retrospective cohort study. Patients from the Icona Foundation study initiating first-line cART between 1997 and 2013 were selected and observed until new-onset DM or most recent clinical follow-up. The predictive value of TRG and TRG/HDL ratio levels on DM was evaluated using multivariable Poisson regression models.
RESULTS: Three-thousand, five-hundred and forty-six patients (males, 73.7%; median age, 38 years; median BMI, 23.1 kg/m(2); and hepatitis C virus antibody positive, 22.1%) were included. Of these, 80 developed DM over 13 911 person-years of follow-up (PYFU), corresponding to 5.7 cases per 1000 PYFU (95% CI = 4.6-7.1). At multivariable analysis, latest TRG/HDL ratio, when high, was associated with significant increases in DM risk [relative risk (RR) = 1.63; 95% CI = 1.32-2.01 per 10 points higher], while current TRG, in contrast, was associated with new-onset DM only at crude analysis. Advanced liver fibrosis (defined as fibrosis-4 index >3.25) was also shown to be an independent risk factor for DM (RR = 2.91; 95% CI = 1.10-7.72).
CONCLUSIONS: High TRG/HDL ratio predicted risk of new-onset DM, independently of other traditional risk factors. Furthermore, our findings suggest that advanced hepatic fibrosis, estimated using the fibrosis-4 score, could provide an additional predictor for DM.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27272727     DOI: 10.1093/jac/dkw185

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Prevalence of obesity and disturbances in glucose homeostasis in HIV-infected subjects and general population - missed diagnoses of diabetes?

Authors:  A Hanttu; K J Kauppinen; P Kivelä; J Ollgren; P Jousilahti; K Liitsola; P Koponen; J Sutinen
Journal:  HIV Med       Date:  2020-11-09       Impact factor: 3.180

2.  Incidence and associated factors of type 2 diabetes mellitus onset in the Brazilian HIV/AIDS cohort study.

Authors:  Alex J F Cassenote; Alexandre Grangeiro; Maria M Escuder; Jair M Abe; Raul D Santos; Aluisio C Segurado
Journal:  Braz J Infect Dis       Date:  2021-08-31       Impact factor: 3.257

3.  Lipid levels and new-onset diabetes in a hypertensive population: the China Stroke Primary Prevention Trial.

Authors:  Leliang Li; Ping Li; Juan Yang; Xiao Huang; Huihui Bao; Chunyan Zhang; Yun Song; Min Zhao; Meng Ji; Yi Wang; Geng Qian; Genfu Tang; Shanqun Jiang; Qiang Dong; Yan Zhang; Jianping Li; Xiping Xu; Binyan Wang; Yong Huo; Xiaoshu Cheng
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

4.  Tumour necrosis factor-related apoptosis-inducing ligand expression in patients with diabetic nephropathy.

Authors:  Wei-Wei Chang; Wei Liang; Xin-Ming Yao; Liu Zhang; Li-Jun Zhu; Chen Yan; Yue-Long Jin; Ying-Shui Yao
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Jul-Sep       Impact factor: 1.636

5.  Epidemiology of undiagnosed type 2 diabetes mellitus among hill tribe adults in Thailand.

Authors:  Tawatchai Apidechkul; Chalitar Chomchoei; Panupong Upala
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.